Controlling the pandemic during the SARS-CoV-2 vaccination rollout: a modeling study

João Viana, MSc^{1,2}, Christiaan H. van Dorp, PhD³, Ana Nunes, PhD^{2,4}, Manuel C. Gomes, PhD², Michiel van Boven, PhD¹, Mirjam E. Kretzschmar, PhD¹, Marc Veldhoen, PhD⁵, and Ganna Rozhnova, PhD^{*1,4}

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

²Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal

³Theoretical Biology and Biophysics (T-6), Los Alamos National Laboratory, Los Alamos, New Mexico, USA

⁴BioISI—Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Lisbon, Portugal

⁵Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

March 24, 2021

*Corresponding author:

Dr. Ganna Rozhnova
Julius Center for Health Sciences and Primary Care
University Medical Center Utrecht
P.O. Box 85500 Utrecht
The Netherlands
Email: g.rozhnova@umcutrecht.nl
Phone: +31 631117965

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

There is a consensus that mass vaccination against SARS-CoV-2 will ultimately end the COVID-19 pandemic. However, it is not clear when and which control measures can be relaxed during the rollout of vaccination programmes. We investigate relaxation scenarios using an age-structured transmission model that has been fitted to age-specific seroprevalence data, hospital admissions, and projected vaccination coverage for Portugal. Our analyses suggest that the pressing need to restart socioeconomic activities could lead to new pandemic waves, and that substantial control efforts prove necessary throughout 2021. Using knowledge on control measures introduced in 2020, we anticipate that relaxing measures completely or to the extent as in autumn 2020 could launch a wave starting in April 2021. Additional waves could be prevented altogether if measures are relaxed as in summer 2020 or in a step-wise manner throughout 2021. We discuss at which point control of COVID-19 would be achieved for each scenario.

Introduction

Mass vaccination against SARS-CoV-2 that started in Europe in December 2020/January 2021 [1] brings hope that the COVID-19 pandemic will end in 2021. Although the progress towards this goal is on the right track [2], many governments in Europe continue limiting socioeconomic activities to control the pandemic. Despite elaborate national vaccination schedules, it remains unclear when and which control measures can be relaxed and at which point the control of the pandemic will be achieved as the vaccination is rolled out in 2021. The understanding of how relaxation policies might affect the transmission of SARS-CoV-2 is further hampered by the emergence of novel variants [3, 4] that have a selective advantage, such as increased transmissibility [5–7] or the ability to reduce rapid neutralisation by the host [8]. For example, the current restrictions in Europe [9] are in part caused by a more transmissible [5–7] and potentially more pathogenic [10, 11] B.1.1.7 variant that originated in the UK and is quickly gaining dominance in other countries including Portugal [12, 13].

The vaccines that have been approved in Europe [14] show consistently high efficacy against severe disease, hospitalization and death in trials [15–17] and equally high effectiveness in real-world settings [18–22]. Multiple studies are under way to establish infection-blocking properties of these vaccines. Preliminary analyses of the national vaccination programme in Israel indicate that the effectiveness of the Pfizer-BioNTech vaccine against asymptomatic SARS-CoV-2 infections could be as high as 94% [21], as announced recently by the Israel Ministry of Health, Pfizer Inc and BioNTech SE. The recent Danish cohort study on long-term care facility residents and healthcare workers suggests that the effectiveness of the Pfizer-BioNTech vaccine based on a positive PCR test for SARS-CoV-2 is 64% and 90% beyond seven days of second dose in the two groups, respectively [19]. Similar results were found in a study among healthcare workers in England where the effectiveness of the Pfizer-BioNTech vaccine against symptomatic and asymptomatic infection was 86% seven days after two doses [22]. Based on the data from Israel, the effectiveness of the same vaccine against infection with SARS-CoV-2 was shown to be 51% 13–24 days after one

dose [20]. Finally, in an analytical study by Lipsitch et al [23], the lower bound for the efficacy against transmission for one dose of Moderna vaccine was estimated at 61% but it could possibly be considerably higher, especially after two doses.

The consequences of relaxing control measures such as e.g., physical distancing, school closure, mask-wearing, test-and-trace and isolation, will depend on several factors, including the properties of vaccines deployed in a given country, specific vaccination schedules and speeds of vaccine rollout, but also the past epidemiology of SARS-CoV-2 that defines a proportion of the population protected after natural SARS-CoV-2 infection [24, 25]. All these factors are naturally country-dependent and will play a major role in how the pandemic will develop under different relaxation scenarios [26–29] and how quickly the control of COVID-19 will be gained in specific countries throughout 2021 and possibly beyond. To make a few distinctive examples, we recall Israel which has the highest vaccination rate worldwide so that, on average, every person has received at least one vaccine dose by mid-March 2021 [1] and Manaus in Brazil, where the levels of protection by natural infection close to the theoretical herd immunity threshold were achieved prior to the start of mass vaccination [30].

An extensive body of literature addresses the challenges of modelling real-time fast-moving COVID-19 pandemic [31]. Mathematical transmission models robustly calibrated to available data are among the best tools available to provide input into the discussion on the response to the COVID-19 pandemic [32–43] and they will continue to play an important role in making decisions surrounding the relaxation of measures in 2021 [26–29]. Several modeling studies provided support for the development of COVID-19 vaccines and early planning of vaccination scenarios and rollouts [44–48], but these models typically assumed that a large proportion of the population is vaccinated instantaneously and/or did not focus on relaxation strategies. More recently, organized teams of modeling experts supporting decision-makers over health emergencies in China and the UK evaluated the roadmap scenarios for relaxation of control measures in these countries in light of ongoing mass vaccination [26–28].

The present study makes a contribution towards better understanding of when and which control measures can be relaxed as mass vaccination programmes progress in 2021. We take Portugal as a case study where good quality data for model parameterization are available but, apart from efforts of genomic surveillance [49], there are no dedicated COVID-19 modeling studies for informing policymaking in this country [50]. Using an age-structured transmission model that has been fitted in a Bayesian framework to the data from various sources (age-specific hospitalizations and seroprevalence, social contact and demographic data, national vaccination plan and vaccine rollout data etc.), we investigate future pandemic trajectories under several alternative relaxation scenarios throughout 2021. Among the explored relaxation strategies are lifting measures to the same extent as in summer 2020 and later on in autumn 2020, the complete lifting of measures and combinations of these. We evaluate the impact of each scenario on the epidemic dynamics as quantified by projected hospital admissions, the time-dependent effective reproduction number, population immunization level due to natural infection and vaccination, and timing of reaching control of COVID-19 in Portugal. Finally, we discuss the implications of our findings for the post-pandemic dynamics of

68 SARS-CoV-2.

Figure 1. Model fit to COVID-19 hospitalizations. The age-stratified daily hospital admission data are shown as red dots. The median trajectories estimated from the model are shown as the black lines. The gray shaded regions correspond to 95% Bayesian prediction intervals based on 2,000 parameter samples from the posterior distribution. Hospital admissions were estimated for 10 age groups (see Methods). For presentation purposes, here we grouped hospitalizations for ages [0,5), [5,10), [10,20).

69 Results

70 Model calibration

71 The model was fitted to age-stratified COVID-19 hospitalization data in the period from 26 February 2020 till 15
 72 January 2021 and cross-sectional age-stratified SARS-CoV-2 seroprevalence data assessed from 21 May 2020 till 8
 73 July 2020. The model reproduces well the age-specific hospital admissions (Figure 1) featuring (i) the first pandemic
 74 wave (March-April 2020), (ii) relatively low epidemic activity (May-August 2020), (iii) the second pandemic wave
 75 (September-mid-December 2020), (iv) the third wave that started in mid-December 2020 and was still ongoing on
 76 15 January 2021 [51]. The estimated hospitalization rates increase with age from 0.12 (95%CrI 0.07-0.23) per year
 77 for children under 5 years of age to 14.24 (95%CrI 9.91-21.23) per year for persons above 80 years (Figure S1). In
 78 agreement with other studies [52, 53], the estimated susceptibility to SARS-CoV-2 increases with age (Figure S2).
 79 The meaning of model parameters is given in Tables S2 and S4, and their estimates are shown in Figures S1 and
 80 S2.

81 The model also reproduces well the age-specific and total seroprevalence in the population (Figure 2). The estimated
 82 age-specific seroprevalence ranged between 1.77% (95%CrI 0.98-2.91%) for 1 to 10 years old children to 4.61%

(95%CrI 3.47–5.91%) for 20 to 40 years old adults (Figure 2 a). The total seroprevalence steadily increased with time reaching 19.37% (95%CrI 14.82–24.57%) on 15 January 2021 (Figure 2 b).

Figure 2. Model fit to SARS-CoV-2 seroprevalence. **a** Age-specific seroprevalence. **b** Total seroprevalence. The data (dots and error bars) are based on the cross-sectional seroepidemiological survey (First National Serological Survey) conducted after the first pandemic wave [54]. **a** The violin shapes represent the marginal posterior distribution of the age-specific seroprevalence in the model. **b** The black line and the gray shaded region show the median total seroprevalence and 95% credible intervals. The uncertainty in the model is based on 2,000 parameter samples from the posterior distribution. The total seroprevalence refers to population older than 1 year [54].

Time-varying contact patterns and effective reproduction number

We estimated how age-specific contact rates in the population changed due to control measures as the pandemic developed. These contact rates denote the average number of transmission-relevant contacts per day a person in a given age category has with persons in other age categories. We further calculated the time-dependent effective reproduction number, $R_e(t)$, defined as the average number of secondary infections caused by one infectious individual in the population with age-specific contact patterns and age-specific seroprevalence at time t . $R_e(t) < 1$ signifies the control of the pandemic with possibly some of control measures in place. The full control of COVID-19 is achieved when $R_e(t) < 1$ and the contact rates in the population are restored to the pre-pandemic level. Our findings are summarized in Figure 3, where we show the total daily hospitalizations (Figure 3 a), the average (over all ages) number of daily contacts in the population (Figure 3 b) and $R_e(t)$ (Figure 3 c) evaluated bi-weekly in the period from 26 February 2020 till 15 January 2021. The green vertical lines indicate the estimated mid-point transitions in the age-specific contact rates (see Methods). The pre-pandemic average number of daily contacts was 12.6. The estimated basic reproduction number (in the absence of control measures and with zero seroprevalence)

Figure 3. Estimated contact rate and effective reproduction number. **a** Total daily hospital admissions with COVID-19. **b** Average (over all ages) number of daily contacts in the population. **c** Effective reproduction number, $R_e(t)$. The average daily contacts and R_e were evaluated once every two weeks. The green vertical lines indicate the estimated mid-point transitions in the age-specific contact rates. The red horizontal line denotes $R_e = 1$. The hospitalization data are shown as red dots. The black solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals.

was 2.20 (95%CrI 1.97–2.56). The control measures introduced during the first wave in spring 2020 reduced the number of contacts to 4.2 (95%CrI 3.3–5.0) and R_e to 0.69 (95%CrI 0.64–0.75). After some of these measures were lifted, the number of contacts increased to 5.9 (95%CrI 5.1–6.6) and R_e increased to almost 1 and stayed nearly constant throughout summer 2020. At the start of the second wave in autumn 2020 that followed the opening of schools and the associated changes in the contact patterns of the rest of the population, the average number of contacts further increased to about 7.6 (95%CrI 6.7–8.3) and R_e to 1.24 (95%CrI 1.21–1.28). The reinforcement of measures during the second wave could only reduce R_e to 0.89 (95%CrI 0.86–0.99) as compared to R_e of 0.69 after more severe measures introduced during the first wave. Finally, the increased activity of the population around Christmas and the New Year 2021 initiated the third wave in January 2021.

Table 1. The Portuguese vaccination plan.

Category	Age (years)	Vaccination period	Persons
Phase 1			937,361
Healthcare workers (HCW)	20 – 65	27 Dec 2020 – 28 Feb 2021	199,708
Long-term care facilities (LTCF)		01 Jan 2021 – 28 Feb 2021	148,119
Residents	65+		86,982
Staff	20 – 65		61,138
Risk Group 1	50+	01 Feb 2021 – 30 Apr 2021	513,634
Cardiac insufficiency			207,571
Coronary heart disease			169,265
Renal insufficiency			8,201
Chronic obstructive pulmonary disease (COPD)			128,597
First response professionals (FRP) (firemen, police, military etc.)	20 – 65	01 Feb 2021 – 30 Apr 2021	75,900
Phase 2			3,333,191
Persons with or without morbidities unvaccinated before*	65+	01 May 2021 – 31 Jul 2021	1,873,349
Risk Group 2	50 – 65	01 May 2021 – 31 Jul 2021	1,459,842
Diabetes			222,864
Neoplasm			114,246
Hepatic insufficiency			93,004
Chronic kidney disease			4,222
Obesity			392,959
High blood pressure			632,547
Phase 3			6,529,448
Remaining persons (excluding children)**	20 – 65	01 Aug 2021 – 31 Dec 2021	6,529,448
Total*			10,800,000

*The Portuguese vaccination plan assumes that all persons in the population will be vaccinated with a two-dose vaccine schedule. In the model, the maximum vaccination coverage in any age group is 90%. **According to the current guidelines, persons under 18 years old are not eligible for vaccination. In the model, we assumed that the age group of 0 to 20 years old is not vaccinated.

Vaccination rollout

We implemented the rollout of vaccination against SARS-CoV-2 as set out by the Directorate-General of Health — a division of Portuguese Ministry of Health concerned with public health (Table 1). The mass vaccination started on 27 December 2020, is planned to proceed in three phases that will cover the whole population of Portugal by 31 December 2021. In the model, we made several simplifying assumptions regarding vaccination, i.e. 1) at most 90% of each age group will be vaccinated (as supported by the survey conducted between 23 January and 5 February 2021 on the willingness to get vaccinated where the percentage of the Portuguese residents who want to get vaccinated exceeds 95% [55]) except for persons under 20 years of age (as supported by the current guidelines on the ineligibility for vaccination of persons under 18 years of age); 2) the distributed vaccine is by BioNTech/Pfizer brand (as supported by the recent ECDC vaccination data for Portugal where 96% of vaccine doses distributed up until February 21, 2021 are by BioNTech/Pfizer); 3) vaccination is modelled as a single event that immediately confers protection equivalent to two vaccine doses; 4) we considered an infection-blocking vaccine and formulated optimistic (main results) and pessimistic (sensitivity analyses) assumptions for vaccine efficacies in reducing infection, disease and severe disease; 5) there is no waning of protection against (re-)infection after natural infection and vaccination. More details of the vaccination model are given in Methods.

We used the rollout schedule (Table 1) and data (Figure 4 a) on the age distribution of morbidities among the Portuguese residents and age distribution of prioritized vaccination categories (e.g., healthcare workers, long-term

Figure 4. Vaccination rollout schedule. **a** Age distribution of vaccination categories. **b** Total vaccination rate (number of persons vaccinated per day, black line) and proportions of vaccination rate attributable to ages [0,20) (blue), [20,60) (yellow) and 60+ (red). The gray vertical lines in **b** indicate the starting dates for different vaccination phases (Table 1). The age-specific vaccination rates are given in Figure S3.

Figure 5. Vaccination coverage during the vaccination rollout. **a** Age-specific coverage (percentage of vaccinated persons per age group). **b** Total vaccination coverage (percentage of vaccinated persons in the population). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1). The coverages for ages [20,30), [30,40), and [40,50) are equal (see Figure S4 for the absolute numbers of vaccinated persons). The coverage for ages [0,20) is zero. The ECDC vaccination rollout data in **b** are shown as red (1 dose) and blue (2 doses) dots.

care facilities staff and residents etc.) to calculate age-specific vaccination rates (number of persons in a given age group vaccinated per day) as the vaccination programme progresses (Figure 4 b; see Figure S3 for detailed information). The vaccination rate refers to vaccination with two vaccine doses. The maximum vaccination coverage of 90% is projected to be reached in the following order (Figure 5 a): 80+ (29 June 2021), [60,80) (20 July–23 July 2021), [50,60) (29 August 2021) and [20,50) (16 November 2021) (see Figure S4 for absolute numbers of vaccinated persons). The total coverage in the population will increase to 9%/38%/73% (maximum coverage) by 1 May/1 August/16 November 2021 (Figure 4 b). The ECDC vaccination rollout data for Portugal agree well with these projections.

Scenarios for relaxation of control measures

To account for the epidemiological situation in Portugal between mid-January and mid-March 2021 [51], we modeled the third wave of hospitalizations that was curbed by the substantial reinforcement of measures similar to those implemented during the first wave in spring 2020. We also modelled an increase in the transmissibility of the virus due to the rapid spread of B.1.1.7. variant in Portugal. The situation in mid-march 2021 is then described by the average number of daily contacts of 4.2, R_e of 0.67 and the circulating variant that is 50% more transmissible [5–7] than the original variant that was dominant in Portugal until December 2020. Starting from this situation, we generated scenarios for relaxation of control measures as follows (Figure 6): Scenario 1) lifting all measures so that contact rates in the population return to the pre-pandemic level (average rate of 12.6 contacts/day); Scenario 2) partial lifting of measures that increases contact rates to the level of September-October 2020 (7.6 contacts/day); Scenario 3) partial lifting of measures that increases contact rates to the level of June-August 2020 (5.9 contacts/day). In accordance with the plan of the Portuguese government to alleviate some of the current measures in spring 2021 and to make the scenarios comparable, we used the same mid-point (1 April 2021) and the same speed of transition between the contact levels (10 days).

The comparative analysis of Scenarios 1, 2, and 3 is shown in Figure 6. The model predicts that lifting all measures (Scenario 1; Figure 6 a-d) launches a fourth wave that is significantly larger than the previous waves, resulting in 58,226 cumulative hospitalizations between 1 April and 1 January 2022 (Figure 6 a). R_e increases sharply from 0.67 on 23 March 2021 to 2.03 two weeks later (Figure 6 c) which is very close to the basic reproduction number of 2.20 at the start of the pandemic. The full control over COVID-19 is reached on 18 May 2021 when R_e drops below 1 and the contact rates are the pre-pandemic level (Figure 6 b). At this threshold, 60% of the population acquired protection after natural infection and only 10% are protected after vaccination (Figure 6 d). Relaxing measures according to Scenario 2 (Figure 6 e-h) initiates a new pandemic wave too, albeit smaller in magnitude than Scenario 1 (8,975 hospitalizations between 1 April and 1 January 2022; Figure 6 e). In this case, R_e becomes smaller than 1 on 29 June 2021 (Figure 6 g) but the measures have to be kept in place (Figure 6 f) to control the spread. The increase of contact rates to the level of June-August 2020 (Scenario 3; Figure 6 i-l), however, does not lead to a rise

Figure 6. Scenarios for relaxation of control measures. a-d Lifting all measures so that contact rates in the population return to the pre-pandemic level. e-h Partial lifting of measures so that contact rates increase to the level of September-October 2020. i-l Partial lifting of measures so that contact rates increase to the level of June-August 2020. The blue vertical lines indicate the mid-point of the transition (1 April 2020). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1). The red horizontal line denotes $R_e = 1$. The hospitalization data are shown as red dots. The thick solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals.

in hospitalizations (Figure 6 i) because R_e stays below 1 (Figure 6 k) but, like in Scenario 2, the measures have to continue until sufficient number of people acquire protection by vaccination to relax them completely. In addition, we explored Scenario 4 (Figure 7) where measures are relaxed in a step-wise manner so that contact rates first rise to the level of June-August 2020 (Step 1, Scenario 3), then to the level of September-October 2020 (Step 2, Scenario 2) and, finally, to the pre-pandemic level (Step 3, Scenario 1) (Figure 7 b). The mid-points of transitions were 1 April, 1 June and 1 October 2021 (blue vertical lines in Figure 7) and the relaxation speed of 10 days was used for all transitions. In this scenario, additional waves can be prevented altogether and hospitalizations stay at the level comparable to that in summer 2020 when the epidemic activity was low (Figure 7 a). Interestingly, Step 2 (1 June) and Step 3 (1 October) increase R_e above 1 (Figure 7 c) leading to waves of infections (Figure S5)

Figure 7. Sequential relaxation of control measures. This scenario consists of sequential relaxation of measures so that the contact rates increase, in sequence, to the level of June-August 2020, of September-October 2020 and the pre-pandemic level. The blue vertical lines indicate the mid-points of these transitions (1 April, 1 June, 1 October). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1). The red horizontal line denotes $R_e = 1$. The hospitalization data are shown as red dots. The thick solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals.

but a large increase in hospitalizations is not observed because a substantial proportion of the vulnerable population has been vaccinated (Figure 5). The full control of the pandemic ($R_e(t) < 1$ and pre-pandemic contact rates) is reached on 8 February 2022 (Figure 7 c) when 36% of the population are protected after natural infection, 48% after vaccination, and 17% stay unprotected (Figure 7 d). This is drastically different from Scenario 1, where the control was reached mainly due to protection through natural infection (60%), and the minority was protected by vaccination (10%).

Finally, we would like to stress that for demonstration purposes the timings of Steps 2 and 3 in Scenario 4 have been intentionally chosen so that the epidemic activity (i.e., the number of hospital admissions) in 2021 is similar to that in summer 2020. The premature relaxation of measures can still lead to new waves of hospitalizations. We demonstrate this in Figure S6 where Step 3 occurs on 1 August instead of 1 October 2021. Similarly, the results presented for Scenario 4 (and other scenarios as well) are the most optimistic in terms of projected hospitalizations and get worse for a pessimistic set of vaccine efficacies or if individuals return to pre-pandemic contact rates immediately upon getting vaccinated (see Figure S7).

Discussion

In this study, we used an age-structured model for SARS-CoV-2 transmission to generate several scenarios for relaxation of control measures during the ongoing vaccination rollout in Portugal. In agreement with the plans of the Portuguese government, the mid-point of easing of measures is April 2021. Our analyses demonstrate that vaccination alone, if rolled out according to the national vaccination schedule, is likely to be insufficient to control the Portuguese pandemic when control measures are significantly alleviated in April 2021. Returning to the pre-pandemic lifestyle already in spring 2021 is the worst-case scenario that would be detrimental for the healthcare system. Even for the most optimistic model assumptions, this scenario would result in a wave of hospitalizations several orders of magnitude larger than the three previous waves. Relaxing measures to the same extent as in autumn 2020 would lead to somewhat smaller wave (as compared to the worst-case scenario and even to the third wave that actually occurred) that would, nonetheless, present a significant burden for the national healthcare. These findings are qualitatively similar to those in modeling studies for China [28] and the UK [26, 27], but the quantitative comparison is not possible because of different settings and contexts in which those studies were conducted. Additional waves could be prevented altogether if measures in spring 2021 are relaxed to the same extent as in summer 2020 or in a step-wise manner throughout 2021.

The point at which the pandemic is brought under full control ($R_e(t) < 1$ and pre-pandemic contact patterns) depends on the amount of protection in the population acquired through a combination of natural infection and vaccination. Gaining the control quickly (by mid-May 2021) occurs mainly through protection by natural infection (60% of the population) while the minority (10%) would be protected by vaccination. As mentioned above, this worst-case scenario is, obviously, undesirable and is not very much different from letting the pandemic develop without any control measures. In the gradual relaxation scenario, achieving control takes more than one year since the start of vaccination rollout, but almost 50% of the population are protected by vaccination and a smaller proportion (35%) have experienced SARS-CoV-2 by that point. Alternative to these scenarios would be accelerating the vaccination campaign so that vaccination coverage increases faster than initially projected and confirmed by the ECDC vaccination rollout data [2]. However, it is not clear whether this option is viable for Portugal given the current shortage for COVID-19 vaccines.

A strength of our analyses is that we calculate the effective reproduction number using the estimated current levels of age-specific seroprevalence and vaccination coverage in the population instead of reducing the value of R_e at the beginning of the pandemic homogeneously across age groups as it is done in e.g. the study for China [28]. Another strength is that, unlike this study [28] and the studies for the UK [26, 27], the parameters of our model are statistically evaluated to match the course of the Portuguese pandemic as reflected by age-specific hospital admissions and age-specific seroprevalence [54]. In addition, our fitting procedure allows for estimation of temporal changes in age-dependent contact patterns as a response to prior control measures during this pandemic. Therefore, instead of modeling specific relaxation policies, that are notoriously hard to implement in mechanistic transmission

models, we model several scenarios using the estimated contact structure after relaxation of measures in summer and autumn 2020.

In light of these past measures, our findings are easy to interpret and contain an important message for local policymakers. School opening is thought to be the main driver of the changes observed in autumn 2020, although an increase in socializing indoors in general caused by weather alone must also have played a role. If the relaxation planned for April 2021 includes school reopening in full after Easter and resuming indoor service in restaurants and bars, then it is very likely that the average contact rate in the population will reach levels very similar to those in autumn 2020. As a consequence, this might lead to a new wave of hospitalizations as illustrated in Scenario 2. On the bright side, according to our analysis the goal of Scenario 3, in which major waves are avoided, seems well within reach, given the light control measures that were in place during summer 2020. Combining these with some additional limitations of indoor social activities and online classes for secondary school students could help to replicate the average contact rate of summer 2020, compensating for opening of elementary schools.

As any model, our model has limitations. An important one is that protection against (re-)infection after natural infection and vaccination is permanent over the time-scale of our analyses (almost two years). This frequently used assumption [26–28, 44, 47] leads to that in our model, theoretically, SARS-CoV-2 can be eliminated from the population. However, as we discussed recently [56] and as addressed in several conceptual modeling studies [57–59], accumulating evidence suggests that after the initial pandemic phase SARS-CoV-2 is likely to be transitioning to endemicity and continued circulation. Specifically, recent data from individual-level studies point to that detectable levels of antibodies to SARS-CoV-2 providing immunity against reinfection can wane on the time scale of a few months to few years following exposure, as shown by our group [60] and corroborated with findings of other studies [61–63]. However, the immunity to SARS-CoV-2 depending on a combination of B- and T-cell-mediated responses elicited during primary SARS-CoV-2 infection could reduce susceptibility to and infectiousness of the following infections and offer protection against severe disease, i.e. COVID-19 [64]. The estimation of the model parameters and evaluation of relaxation strategies in light of waning of sterilizing immunity lies outside the scope of our study but it should be addressed in future work when convincing data on reinfections in unvaccinated and vaccinated individuals become available.

Another limitation is that our results are based on early data on the efficacy in clinical trials and real-world effectiveness of the Pfizer-BioNTech vaccine [15, 18–22]. We also assume that vaccine efficacy against the B.1.1.7 variant circulating in Portugal is the same as the efficacy reported from studies conducted in other locations as supported by the recent study among working age adults in England [22], where the dominant variant in circulation was B.1.1.7. This study demonstrated that effectiveness of the Pfizer-BioNTech vaccine against symptomatic and asymptomatic infection is 86% seven days after two doses [22]. However, SARS-CoV-2 mass vaccination programmes and prolonged control measures can generate selection pressure leading to viral adaptation, antigenic divergence or vaccine escape. Viral adaptations may contribute to decreasing efficacy of existing vaccines via faster waning

of sterilizing immunity. For example, recent experiments demonstrate that the South African variant B.1.351 shows reduced neutralizing antibody binding increasing the prospects of reinfection and hampering the efficacy of spike-based vaccines [65]. This will need consideration in vaccine development and evaluation of future vaccination programmes and relaxation scenarios in mathematical transmission models. A possible case where an antigenic escape variant caused a resurgence of COVID-19 despite high population-level seroprevalence was observed in Manaus, Brazil [30].

To summarize, our study provides timely input into the discussion about the pandemic response during the vaccination rollout in Portugal. Our analyses suggest that the pressing need to restart socioeconomic activities might lead to new waves of hospitalizations in 2021 and that substantial measures prove necessary to control COVID-19 throughout 2021. More favourable scenarios that help to avoid future waves include relaxation of measures as in summer 2020 or a step-wise approach when measures are relaxed gradually until the end of 2021.

Methods

Overview

The transmission model was calibrated using a combination of behavioral, surveillance and demographic data for Portugal. Parameter estimates were obtained from the model fit to (i) age-stratified COVID-19 hospitalization data ($n = 28,482$) in the period from 26 February 2020 till 15 January 2021 and (ii) cross-sectional age-stratified SARS-CoV-2 seroprevalence data ($n = 2,301$) assessed from 21 May 2020 till 8 July 2020 [54]. The model was further used to investigate relaxation scenarios as vaccination is rolled out in 2021.

Data

The hospitalization data included $n = 28,482$ COVID-19 hospitalizations longer than 24 hours by date of admission and stratified by age during the period of 325 days following the first official case in Portugal (2 March 2020). The data was padded with 5 days without hospitalizations (from 26 February till 1 March 2020) to allow for the estimation of the number of infected individuals at the start of the pandemic. The hospitalization data spanned the first wave in spring 2020, relatively low epidemic activity in summer 2020, the second wave that started in autumn 2020 till mid-December 2020 and the third wave that started in mid-December 2020 and was still ongoing on 15 January 2021. The data source for hospital data was the Central Administration of the Health System and the Shared Services of the Ministry of Health, covering all public hospitals in Portugal receiving COVID-19 patients. Since early in the pandemic, Portugal adopted a policy of hospitalizing only patients who did not gather minimum conditions for being followed at the domicile, either due to clinical or sanitary conditions. This policy has not changed during the course of the pandemic.

The SARS-CoV-2 seroprevalence data was based on the First National Serological Survey (ISNCOVID-19) in

Portugal in May/July 2020 [54]. This cross-sectional seroepidemiological survey was conducted on a sample of $n = 2,301$ Portuguese residents, aged 1 year or older, after the first wave. The survey sample was selected using a two-stage stratified non-probability sampling design (quota sampling) [54]. SARS-CoV-2 IgM and IgG antibodies were measured in serum samples by enzyme-linked immunosorbent assay. Further details of the study are given in [54]. For the model fitting, we used the sample size, the number of positive samples and 95% confidence intervals stratified by age group reported in [54].

The demographic composition of the Portuguese residents was taken for 2019 from the Contemporary Portugal Database (Pordata) [66]. The vaccination analyses made use of the vaccination programme (Table 1), as defined by the Directorate-General of Health [51]. The programme defines vaccine uptake prioritization by age and morbidities and runs in three phases from 27 December 2020 till 31 December 2021. The age distribution of morbidities in the Portuguese population was extracted from the Shared Services of the Ministry of Health on the basis of ICPC-2 (International Classification of Primary Care) codes (Table S1). The vaccination rollout data for Portugal was taken from the ECDC website.

The baseline (pre-pandemic) contact matrices for transmission-relevant contacts for Portugal were taken from the recent study by Mistry and colleagues [67]. The contact matrix for Portugal after the introduction of measures to control the first wave of hospitalizations (April 2020) was inferred using the contact matrix for the Netherlands based on a cross-sectional survey carried out in April 2020 (PIENTER Corona study) [68].

Figure 8. Schematic of the transmission model. Gray arrows show epidemiological transitions. Red dashed boxes indicate compartments contributing to the forces of infection. The model is age-structured and involves an extended SEIR-type framework. Vaccinated persons may experience behavior compensation post-vaccination modelled as a return to pre-pandemic contact rates among vaccinated persons as compared to unvaccinated persons who may continue to have reduced contact rates due to control measures. The vaccine has three effects: (i) reduction in susceptibility of vaccinated relative to unvaccinated (VE_S); (ii) reduction in infectivity of vaccinated relative to unvaccinated (VE_I , not shown); (iii) reduction in hospitalization rate of vaccinated relative to unvaccinated (VE_H).

Transmission model

We extended an age-stratified SARS-CoV-2 transmission model from [43] to include vaccination (Figure 8). The model has susceptible-exposed-infectious-recovered structure, whereby susceptible persons (S) may become latently infected (E) before progressing to become infectious (I). Infectious persons either get hospitalized (H) or recover without hospitalization (R). Disease-related mortality and discharge from the hospital are not explicitly modeled. Therefore, the H -compartment contains the cumulative number of persons who experience severe symptoms and recover (or die) after admission to the hospital. Similarly, the R -compartment contains the cumulative number of persons who recover after having mild or no symptoms. The force of infection is given by a weighted sum of the fraction of the infectious population in different age groups (red dashed boxes in Figure 8). We consider a stable population and thus do not include natural birth and death processes. The contact rates, forces of infection, susceptibilities and hospitalization rates are age-specific.

In line with the current guidelines, we assume that vaccine can be delivered to all people independently from their disease history with the exception of those who might be currently infectious (I -compartment). Not vaccinating infectious compartment implies that vaccine is not given to asymptomatic persons but these represent a small fraction of the population at any given time. We also vaccinate the H -compartment as this compartment comprises everyone who has ever been admitted to hospital. Whilst this assumption means that the currently hospitalized persons are vaccinated too, their number is very small compared to the total number of people in the H -compartment. The vaccine has three mechanisms of action: (i) reducing susceptibility (VE_S); (ii) reducing infectivity (VE_I); (iii) reducing hospitalization rate (VE_H). The vaccine has no effect in persons who recovered from natural infection (R and H compartments). We assume that protection after vaccination is achieved immediately and is equivalent to two vaccine doses, and that the duration of protection after both natural infection and vaccination is about two years (time horizon of our analyses). Finally, we allow for behavior compensation post-vaccination modelled as a return to pre-pandemic contact rates among vaccinated persons as compared to unvaccinated persons who may continue to have reduced contact rates due to control measures. This is reflected in generally different forces of infection for unvaccinated and vaccinated persons. The full description of the model parameters is given in Tables S2 and S4.

Model equations

The model was implemented in Mathematica 10.0.2.0 using a system of ordinary differential equations for the number of persons in different compartments shown in Figure 1. The transmission model was stratified into $n = 10$ age groups: $[0, 5)$, $[5, 10)$, $[10, 20)$, $[20, 30)$, $[30, 40)$, $[40, 50)$, $[50, 60)$, $[60, 70)$, $[70, 80)$, $80+$.

The equations for the numbers of unvaccinated persons in age group k , $k = 1, \dots, n$, who are susceptible (S_k),

exposed (E_k), infectious (I_k), recovered (R_k) and hospitalized (H_k) read as follows

$$\begin{aligned}\frac{dS_k(t)}{dt} &= -\beta_k \lambda_k(t) S_k(t) - \frac{r_k S_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\ \frac{dE_k(t)}{dt} &= \beta_k \lambda_k(t) S_k(t) - \alpha E_k(t) - \frac{r_k E_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\ \frac{dI_k(t)}{dt} &= \alpha E_k(t) - (\gamma + \nu_k) I_k(t), \\ \frac{dR_k(t)}{dt} &= \gamma I_k(t) - \frac{r_k R_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\ \frac{dH_k(t)}{dt} &= \nu_k I_k(t) - \frac{r_k H_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}.\end{aligned}\tag{1}$$

The equations for the numbers of vaccinated persons in age group k who are vaccinated susceptible (S_k^V), exposed (E_k^V), infectious (I_k^V), recovered (R_k^V) and hospitalized (H_k^V) are given by

$$\begin{aligned}\frac{dS_k^V(t)}{dt} &= -\beta_k(1 - VE_S) \lambda_k^V(t) S_k^V(t) + \frac{r_k S_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\ \frac{dE_k^V(t)}{dt} &= \beta_k(1 - VE_S) \lambda_k^V(t) S_k^V(t) - \alpha E_k^V(t) + \frac{r_k E_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\ \frac{dI_k^V(t)}{dt} &= \alpha E_k^V(t) - (\gamma + \nu_k(1 - VE_H)) I_k^V(t), \\ \frac{dR_k^V(t)}{dt} &= \gamma I_k^V(t) + \frac{r_k R_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}, \\ \frac{dH_k^V(t)}{dt} &= \nu_k(1 - VE_H) I_k^V(t) + \frac{r_k H_k(t)}{S_k(t) + E_k(t) + R_k(t) + H_k(t)}.\end{aligned}\tag{2}$$

Persons get vaccinated in S , E , R and H states. The vaccination rates r_k are age-specific. We denote the contact rate of an unvaccinated person in age group k with persons in age group l , $c_{kl}(t)$, and the contact rate of a vaccinated person in age group k with persons in age group l , $c_{kl}^V(t)$. The forces of infection for unvaccinated and vaccinated persons are given by

$$\lambda_k(t) = \epsilon \sum_{l=1}^n c_{kl}(t) \frac{I_l(t) + (1 - VE_I) I_l^V(t)}{N_l},\tag{3}$$

$$\lambda_k^V(t) = \epsilon \sum_{l=1}^n c_{kl}^V(t) \frac{I_l(t) + (1 - VE_I) I_l^V(t)}{N_l},\tag{4}$$

where N_k is the number of individuals in age group k , $N_k = S_k(t) + E_k(t) + I_k(t) + H_k(t) + R_k(t) + S_k^V(t) + E_k^V(t) + I_k^V(t) + R_k^V(t) + H_k^V(t)$. Note that Eqs. (3) and (4) imply that the entire population participates in the contact process including persons in the H -compartment but that H -persons are not infectious. This is based on the fact that the vast majority of people in the H -compartment are recovered after hospitalization, and a very small proportion is currently hospitalized. We assume that currently hospitalized persons continue to have contacts with the personnel and visitors but they cannot infect them because of the use of individual protective measures.

The initial condition for the model was $E_k(t=0) = I_k(t=0) = \frac{1}{2}\theta N_k$ and $S_k(t=0) = (1-\theta)N_k$, where $t=0$ is 26 February 2020. The parameter θ denotes the initial fraction of the population that was infected (split equally between infectious and exposed). This parameter accounts for importation of new cases at the start of the pandemic and was estimated jointly with other parameters. Importation of cases was not implemented at later stages of the pandemic due to a large pool of infectious individuals within the country.

The rapid spread of B.1.1.7 variant, that is estimated to be about 50% more transmissible based on the data from England [5–7], fueled the third wave of hospitalizations in Portugal. The increasing dominance of this variant was modelled empirically as a gradual increase in the probability of transmission per contact by 50% as follows $\epsilon[1 + 0.5/(1 + e^{-K_0(t-t_{\text{data}})})]$, where ϵ and K_0 were estimated based on the data until 15 January 2021 (Figure S2) and t_{data} is the last date in the hospital admission data (15 January 2021).

Observation model and parameter estimation

To generate a set of plausible parameters and initial conditions for our projections, we fitted the model to hospitalization data and serological testing data, using a similar approach as before [43, 69]. We incorporated the transmission model, Eq. (1), in a Bayesian statistical model with likelihood function constructed as follows. Let $h_{k,m}$ denote the observed number of hospitalizations in age group k and day t_m . The expected number of hospitalizations during day t_m is approximately equal to $\bar{h}_{k,m} := \nu_k \cdot I_k(t_m)$. To account for reporting errors and heterogeneity in the hospitalization rate within age groups, we assume that $h_{k,m}$ has a negative-binomial distribution with mean $\bar{h}_{k,m}$ and variance $\bar{h}_{k,m} \cdot (1 + \bar{h}_{k,m}/\phi)$. The parameter ϕ determines the overdispersion of the reporting of hospitalizations. The hospitalization data were stratified into the ten age groups $[0, 5)$, $[5, 10)$, $[10, 20)$, $[20, 30)$, $[30, 40)$, $[40, 50)$, $[50, 60)$, $[60, 70)$, $[70, 80)$, $80+$.

The seroprevalence data were stratified into the five age groups $[1, 10)$, $[10, 20)$, $[20, 40)$, $[40, 60)$ and $60+$ [54]. Hence, for the hospitalization data and the transmission model, a finer age stratification is used than for the seroprevalence data. We assume that individuals in seroprevalence age group G_i^s were sampled from hospitalization age class G_k^h with probability p_{ik} proportional to the relative population size of G_k^h compared to G_i^s , i.e.

$$p_{ik} = N_k/N_i^s, \quad \text{where} \quad N_i^s = \sum_{\ell: G_\ell^h \subseteq G_i^s} N_\ell. \quad (5)$$

As before [43], we assume that the seroprevalence data represents a random sample from each age group. Hence, the number of positive samples ℓ_i has a binomial distribution with population size L_i , equal to the total number of samples for age class i , and success probability q_i . The success probability is defined in terms of the fraction of susceptible individuals $S_k(T)$ at sampling time T and the probabilities p_{ik} :

$$q_i = \sum_{k: G_k^h \subseteq G_i^s} (1 - S_k(T)/N_k) p_{ik} \quad (6)$$

To account for the fact that no children below the age of 1 year were included in the serology samples, we reduced the population size N_1 with the size of the age group $[0, 1)$ (86,579 persons) in Eq. (6) and Eq. (5).

The prior distribution of the model is specified in Table S3. The model was fitted with Stan [70] in R 3.6.0 and R Studio 1.3.1056. We used 4 parallel chains, each of length 1,000, with a warm-up period of 500, resulting in 2,000 samples from the posterior distribution. Convergence was assessed with the Gelman-Rubin $\hat{R}$ -statistic, which was close to 1 for all parameters. The estimated model parameters are shown in Figures S1 and S2.

Time-varying contact patterns

The contact patterns in the population varied with time due to introduction/reinforcement or relaxation of control measures as follows: 0) introduction of measures to control the first pandemic wave (first lockdown, March 2020); 1) relaxation of measures after the first wave was curbed (May 2020); 2) further relaxation of measures that included school opening (September 2020); 3) reinforcement of measures to control the second wave (second lockdown, November 2020); 4) relaxation of measures around Christmas 2020; 5) reinforcement of measures to control the third wave (third lockdown, January 2021).

We denote $c_{kl}(t)$ the contact rate for a person in age group k ($k = 1, \dots, n$) with persons in age group l ($l = 1, \dots, n$) at time t . The contact rate denotes the number of transmission-relevant contacts per day such as touching or having a conversation with someone [67, 68]. Our fitting procedure allows to estimate $c_{kl}(t)$ by assuming that changes due to control measures described in 0)-5) occur as a series of smooth transitions.

To describe the transition 0) from the baseline (pre-pandemic) contact rate b_{kl} to the contact rate after the first lockdown a_{kl} we write down $c_{kl}(t)$ as a linear combination of contact rates b_{kl} and a_{kl} with coefficients constructed using a logistic function $f_0(t) = 1 / (1 + e^{-K_0(t-t_0)})$ as follows

$$c_{kl}(t) = [1 - f_0(t)]b_{kl} + f_0(t)\zeta a_{kl}. \quad (7)$$

The parameter K_0 of the logistic function describes the speed with which the first lockdown is enforced. The parameter t_0 describes the mid-time of the introduction of the first lockdown. Note in Eq. 7 we introduced the factor $\zeta \in [0, 1]$ to reflect that not all reported contacts after the first lockdown might be relevant for transmission, for example, due to mask-wearing or physical distancing when a contact took place. Therefore, the baseline (pre-pandemic) contact rates are described by the matrix b_{kl} , and the contact rates after the first lockdown are described by the matrix ζa_{kl} .

The pre-pandemic matrix b_{kl} for Portugal was taken from [67] (Figure 9 a). The matrix after the first lockdown a_{kl} was inferred using the contact matrix for the Netherlands based on a cross-sectional survey carried out in April 2020 (PIENTER Corona study) [68]. Since measures enforced during the first lockdown in the two countries were similar (e.g., all schools were closed, all non-essential work was done from home etc.) we reduced the age-specific

Figure 9. Contact matrices. **a** Baseline (pre-pandemic) contact matrix. **b** Contact matrix after the introduction of measures in April 2020. **c** Average number of contacts for a person in a given age group. **d** Logistic functions describing transitions between contact matrices. Shown are f_0 (blue), f_1 (dark green), f_2 (light green), f_3 (orange), and f_4 (red) based on 50 samples from the posterior distribution.

contact rates for Portugal after the lockdown by the same percentage as it was observed in the Netherlands (Figure 9 b). The resulting number of daily contacts for a person in given age group at baseline and after the lockdown in April 2020 is shown in Figure 9 c. Like for the Netherlands [68], we observe larger reductions in contacts for children (due to school closure) and smaller reductions for elderly because most of their contacts were essential (e.g., with healthcare personnel or caretakers) and thus were not affected by the lockdown. The parameter ζ that multiplies the inferred matrix a_{kl} can account for discrepancies between the real and inferred matrix. To describe the contact rates after transitions 1)-4) have taken place, we assume that these can be written as a liner combination $u_i b_{kl} + (1 - u_i) \zeta a_{kl}$, $i = 1, \dots, 4$, where u_i is the proportion of time a person behaves as before the pandemic and $(1 - u_i)$ is, respectively, the proportion of time a person behaves as during the first lockdown. This contact structure can, therefore, interpolate between the first (most strict) lockdown and no measures in place at all. Since the third lockdown was similar to the first lockdown, the transition 5) was modelled as a return to the lockdown contact matrix ζb_{kl} . As before, the transitions between the contact rates during periods 1)-5) are modelled using logistic functions $f_i(t) = 1 / (1 + e^{-K_i(t-t_i)})$, where $i = 1, \dots, 5$. The general contact rate can therefore be written as

$$\begin{aligned} c_{kl}(t) = & [1 - f_0(t)]b_{kl} + f_0(t)\zeta a_{kl}[1 - f_1(t)] + f_1(t)[u_1 b_{kl} + (1 - u_1)\zeta a_{kl}][1 - f_2(t)] \\ & + f_2(t)[u_2 b_{kl} + (1 - u_2)\zeta a_{kl}][1 - f_3(t)] + f_3(t)[u_3 b_{kl} + (1 - u_3)\zeta a_{kl}][1 - f_4(t)] \\ & + f_4(t)[u_4 b_{kl} + (1 - u_4)\zeta a_{kl}][1 - f_5(t)] + f_5(t)\zeta a_{kl}. \end{aligned} \quad (8)$$

All the parameters that describe $c_{kl}(t)$, except for the last transition 5) for which hospitalization data are not available, are estimated (Table S4). The estimates for these 15 parameters ζ , u_i ($i = 1, \dots, 4$), t_i ($i = 0, \dots, 4$) and K_i ($i = 0, \dots, 4$) are shown in Figure S2. The estimated logistic functions are plotted in Figure 9 d.

In the main analyses (Figures 6 and 7), the contact rates for vaccinated persons were equal to those unvaccinated, $c_{kl}^V(t) = c_{kl}(t)$. In the sensitivity analyses (Figure S7), they were set to pre-pandemic contacts as follows, $c_{kl}^V(t) = b_{kl}$.

The contact rate presented in Figures 3, 6 and 7 was the average contact rate in the population calculated as follows $\langle c(t) \rangle = \sum_{k=1}^n \sum_{l=1}^n c_{kl}(t) N_k / \sum_{k=1}^n N_k$. Note that this expression makes use of the fact that in the main analyses $c_{kl}^V(t) = c_{kl}(t)$.

The relaxation scenarios during the vaccination rollout are modelled as a transition from the contact rate described by Eq. (8) to the contact rate b_{kl} (Scenario 1); $u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$ (Scenario 2); $u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$ (Scenario 3); $u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$ (Scenario 4, Step 1); $u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$ (Scenario 4, Step 2); b_{kl} (Scenario 4, Step 3). The parameters of the logistic functions describing these transitions are specified in Table S4.

Time-varying effective reproduction number

The basic reproduction number, R_0 , is the average number of secondary infections caused by a single infectious individual at the beginning of the epidemic in a disease-free, totally susceptible population. If $R_0 > 1$ the disease will spread exponentially. If $R_0 < 1$ the number of infectious persons declines exponentially and the disease is not able to spread. In general, R_0 depends on the type of virus but also on the contact patterns in the population.

When the disease has already spread and we have no longer a fully susceptible population but some part of the population is immune due to natural infection or vaccination, the generalization of R_0 is given by the effective reproduction number, $R_e(t)$. $R_e(t)$ depends on the type of virus, the level of population immunity and the contact patterns in the population. The full control of the disease is achieved when $R_e(t) < 1$ and the contact rates in the population are at their pre-pandemic levels, i.e., not anymore affected by control measures. A partial control is achieved when $R_e(t) < 1$ but the contact rates have not been restored to their pre-pandemic levels yet as is currently the case for SARS-CoV-2 in Portugal.

In a deterministic compartmental model such as the one employed here, the calculation of R_0 and $R_e(t)$ can be performed using the next-generation matrix (NGM) method [71]. The starting point of the method is to calculate the Jacobian $\mathbf{J}$ of the equations for the latent (E_k, E_k^V) and infectious (I_k, I_k^V) age classes $k, k = 1, \dots, n$, isolated from the full model given by Eqs. (1) and (2). The Jacobian $\mathbf{J}$ is then evaluated at the disease-free equilibrium of interest.

For R_0 calculation, the disease-free equilibrium is

$$S_k^* = N_k, \quad S_k^{V*} = E_k^* = E_k^{V*} = I_k^* = I_k^{V*} = 0, \quad k = 1, \dots, n. \quad (9)$$

For $R_e(t)$ calculation with or without vaccination, the disease-free equilibrium is

$$S_k^* = S_k(t), \quad S_k^{V*} = S_k^V(t), \quad E_k^* = E_k^{V*} = I_k^* = I_k^{V*} = 0, \quad r_k = 0, \quad k = 1, \dots, n, \quad (10)$$

where the time-dependent variables $S_k(t)$ and $S_k^V(t)$ are obtained from the solutions of the full model given by Eqs. (1) and (2).

Following [71], the Jacobian $\mathbf{J}$ may be recast as follows

$$\mathbf{J} = \mathbf{T} + \mathbf{\Sigma}, \quad (11)$$

where the transmissions matrix $\mathbf{T}$ contains the terms associated with the production of new infections, and the transitions matrix $\mathbf{\Sigma}$ contains the terms associated with all other state changes. After performing this operation,

we construct a new matrix $\mathbf{K}_L$, called the large domain NGM [71], given by

$$\mathbf{K}_L = -\mathbf{T}\mathbf{\Sigma}^{-1}. \quad (12)$$

The basic reproduction number R_0 at time $t = 0$ and the effective reproduction number $R_e(t)$ at any time t are given by the spectral radius of $\mathbf{K}_L$ which is the largest eigenvalue of $\mathbf{K}_L$. For the purpose of computing the spectral radius, $\mathbf{K}_L$ can be further reduced as detailed in [71]. The explicit expressions for matrices $\mathbf{J}$, $\mathbf{T}$, $\mathbf{\Sigma}$ and $\mathbf{K}_L$ are given in the Mathematica notebooks available in the GitHub repository, <https://github.com/lynxgav/COVID19-vaccination>.

Population immunity

The unprotected population was computed as the number of individuals in the fully susceptible compartment S (Figure 8). The population protected by natural infection was computed as all individuals arriving into the infectious compartment I , independently of whether these individuals will or will not be vaccinated later on. Recall, that in the model vaccine has no effect in individuals who are recovered from natural infection and, therefore, the population protected by vaccination grows slower than vaccination coverage. The population protected by vaccination was computed as all individuals arriving into the compartments S^V and I^V due to vaccination.

Vaccine efficacies

Vaccine efficacies in reducing susceptibility (VE_S), infectivity (VE_I) and hospitalization rate (VE_H) were set using initial data from clinical trials and real-word studies for the Pfizer-BioNTech vaccine [15, 18–22]. Important to note, that the efficacies reported in all these studies are not conditioned on infection while they are in the models like ours. For a more complete discussion on this topic, we refer the reader to the pedagogical work by Lipsitch and Kahn [23] and the report for England by the Scientific Advisory Group for Emergencies [26].

The vaccine efficacy in reducing susceptibility (VE_S) was set based on vaccine efficacies and effectiveness against infection ($VE_{\text{infection}}$) reported in clinical trials and real-word studies, i.e.

$$VE_{\text{infection}} \equiv VE_S. \quad (13)$$

The vaccine efficacy in reducing infectivity (VE_I) was assumed to be the same as vaccine efficacy in reducing disease conditioned on infection ($VE_{\text{disease}|\text{infection}}$), i.e. $VE_{\text{disease}|\text{infection}} \equiv VE_I$. $VE_{\text{disease}|\text{infection}}$ was calculated using the efficacy against disease (VE_{disease}) reported in clinical trials as follows

$$VE_{\text{disease}} = VE_{\text{infection}} + (1 - VE_{\text{infection}})VE_{\text{disease}|\text{infection}}. \quad (14)$$

The vaccine efficacy in reducing hospitalization rate (VE_H) is equal to vaccine efficacy against severe disease con-

ditioned on disease ($VE_{\text{severe disease}|\text{disease}}$), i.e. $VE_{\text{severe disease}|\text{disease}} \equiv VE_H$. $VE_{\text{severe disease}|\text{disease}}$ was calculated using the vaccine efficacy against severe disease ($VE_{\text{severe disease}}$) reported in trials as follows

$$VE_{\text{severe disease}} = VE_{\text{infection}} + (1 - VE_{\text{infection}})VE_{\text{disease}|\text{infection}} + (1 - VE_{\text{infection}})(1 - VE_{\text{disease}|\text{infection}})VE_{\text{severe disease}|\text{disease}}. \quad (15)$$

We used an optimistic and a pessimistic set of vaccine efficacies for VE_S , VE_I and VE_H (Table S2) based on the range of values for $VE_{\text{infection}}$, VE_{disease} , and $VE_{\text{severe disease}}$ reported in the literature [15, 18–22]. For the optimistic set explored in the main analyses (Figures 6 and 7), we used $VE_{\text{infection}} = 94\%$, $VE_{\text{disease}} = 94\%$, and $VE_{\text{severe disease}} = 98\%$ (corresponding to $VE_S = 94\%$, $VE_I = 0\%$, and $VE_H = 67\%$) [15, 18, 19, 21, 22, 26]. For the pessimistic set explored in sensitivity analyses (Figure S7), we used $VE_{\text{infection}} = 55\%$, $VE_{\text{disease}} = 55\%$, and $VE_{\text{severe disease}} = 55\%$ (corresponding to $VE_S = 55\%$, $VE_I = 0\%$, and $VE_H = 0\%$) [19, 20, 26]. Other efficacies reported in the literature for the Pfizer-BioNTech vaccine and other existing vaccines fall in between the optimistic and pessimistic values we used. This broad range of values is also relevant in case the market share of different vaccine brands in Portugal gets changed throughout 2021.

Data availability

The data used in this study are publicly available at <https://github.com/lynxgav/COVID19-vaccination>.

Code availability

The codes reproducing the results of this study are publicly available at <https://github.com/lynxgav/COVID19-vaccination>.

References

- [1] Coronavirus (COVID-19) vaccinations; 2021. Available from: <https://ourworldindata.org/covid-vaccinations>.
- [2] The European Centre for Disease Prevention and Control COVID-19 Vaccine Tracker; 2021. Available from: <https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>.
- [3] Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants. *Cell*. 2021;184(5):1127–1132. doi:10.1016/j.cell.2021.01.044.

- [4] The European Centre for Disease Prevention and Control Risk Assessment: Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA first update ; 21 January, 2021. Available from: <https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-spread-new-variants-concern-eueea-first-update>.
- [5] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;doi:10.1126/science.abg3055.
- [6] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv. 2021;doi:10.1101/2020.12.30.20249034.
- [7] Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility. medRxiv. 2021;doi:10.1101/2021.01.28.21250680.
- [8] Li Q, Nie J, Wu J, Zhang L, Ding R, Wang H, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;doi:https://doi.org/10.1016/j.cell.2021.02.042.
- [9] Priesemann V, Balling R, Brinkmann MM, Ciesek S, Czypionka T, Eckerle I, et al. An action plan for pan-European defence against new SARS-CoV-2 variants. The Lancet. 2021;397(10273):469–470. doi:10.1016/S0140-6736(21)00150-1.
- [10] Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021;doi:10.1038/s41586-021-03426-1.
- [11] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372. doi:10.1136/bmj.n579.
- [12] The European Centre for Disease Prevention and Control Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update; 15 February, 2021. Available from: <https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021>.
- [13] Gozzi N, Chinazzi M, Davis JT, Mu K, y Piontti AP, Ajelli M, et al. Estimating the spreading and dominance of SARS-CoV-2 VOC 202012/01 (lineage B.1.1.7) across Europe. medRxiv. 2021;doi:10.1101/2021.02.22.21252235.
- [14] European Medicines Agency COVID-19 vaccines: authorised; 2021. Available from: <https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised>.

- 552 [15] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of
553 the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020;383(27):2603–2615.
554 doi:10.1056/NEJMoa2034577.
- 555 [16] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the
556 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised con-
557 trolled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-
558 6736(20)32661-1.
- 559 [17] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273
560 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
- 561 [18] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-
562 19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 0;0(0):null.
563 doi:10.1056/NEJMoa2101765.
- 564 [19] Moustsen-Helms IR, Emborg HD, Nielsen J, Nielsen KF, Krause TG, Mølbak K, et al. Vaccine effectiveness
565 after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and
566 healthcare workers – a Danish cohort study. medRxiv. 2021;doi:10.1101/2021.03.08.21252200.
- 567 [20] Chodick G, Tene L, Patalon T, Gazit S, Tov AB, Cohen D, et al. The effectiveness of the first dose of
568 BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence.
569 medRxiv. 2021;doi:10.1101/2021.01.27.21250612.
- 570 [21] Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public
571 Health Impact of Vaccination One Year After Pandemic Declared; 2021. Available from: [https://www.
572 businesswire.com/news/home/20210311005482/en/](https://www.businesswire.com/news/home/20210311005482/en/).
- 573 [22] Hall, Victoria Jane and Foulkes, Sarah and Saei, Ayoub and Andrews, Nick and Oguti, Blanche and Charlett,
574 Andre and Wellington, Edgar and Stowe, Julia and Gillson, Natalie and Atti, Ana and Islam, Jasmin and
575 Karagiannis, Ioannis and Munro, Katie and Khawam, Jameel and Group, The SIREN Study and Chand,
576 Meera A and Brown, Colin and Ramsay, Mary E and Bernal, Jamie Lopez and Hopkins, Susan. Effectiveness
577 of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in
578 England, Multicentre Prospective Cohort Study (the SIREN Study); 2021. Available from: [http://dx.doi.
579 org/10.2139/ssrn.3790399](http://dx.doi.org/10.2139/ssrn.3790399).
- 580 [23] Lipsitch M, Kahn R. Interpreting vaccine efficacy trial results for infection and transmission. medRxiv.
581 2021;doi:10.1101/2021.02.25.21252415.

- 582 [24] Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with
583 SARS-CoV-2: a systematic review and meta-analysis. *The Lancet Global Health*. XXXX;doi:10.1016/S2214-
584 109X(21)00026-7.
- 585 [25] Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-
586 CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clinical Microbiology and Infection*.
587 2021;27(3):331–340. doi:10.1016/j.cmi.2020.10.020.
- 588 [26] Scientific Advisory Group for Emergencies. Imperial College London: Unlocking roadmap scenarios for
589 England, 18 February 2021; 2021. Available from: [https://www.gov.uk/government/publications/
590 imperial-college-london-unlocking-roadmap-scenarios-for-england-18-february-2021](https://www.gov.uk/government/publications/imperial-college-london-unlocking-roadmap-scenarios-for-england-18-february-2021).
- 591 [27] Moore S, Hill EM, Tildesley MJ, Dyson L, Keeling MJ. Vaccination and non-pharmaceutical interventions
592 for COVID-19: a mathematical modelling study. *The Lancet Infectious Diseases*. XXXX;doi:10.1016/S1473-
593 3099(21)00143-2.
- 594 [28] Yang J, Marziano Vea. Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle?;
595 2021.
- 596 [29] Bauer S, Contreras S, Dehning J, Linden M, Iftexhar E, Mohr SB, et al.. Relaxing restrictions at the pace of
597 vaccination increases freedom and guards against further COVID-19 waves in Europe; 2021.
- 598 [30] Sabino EC, Buss LF, Carvalho MPS, Prete Jr CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19
599 in Manaus, Brazil, despite high seroprevalence. *The Lancet*. 2021;397(10273):452–455. doi:10.1016/S0140-
600 6736(21)00183-5.
- 601 [31] Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, et al. Key ques-
602 tions for modelling COVID-19 exit strategies. *Proceedings of the Royal Society B: Biological Sciences*.
603 2020;287(1932):20201405. doi:10.1098/rspb.2020.1405.
- 604 [32] Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wiggert JHHM, Bonten MJM. Impact
605 of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *The Lancet Public
606 Health*. 2020;5(8):e452–e459. doi:10.1016/S2468-2667(20)30157-2.
- 607 [33] Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection fa-
608 cilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science*. 2020;368(6490):489–493.
609 doi:10.1126/science.abb3221.
- 610 [34] Chang SL, Harding N, Zachreson C, Cliff OM, Prokopenko M. Modelling transmission and control of the
611 COVID-19 pandemic in Australia. *Nature Communications*. 2020;11(1):5710. doi:10.1038/s41467-020-19393-6.

[35] Teslya A, Pham TM, Godijk NG, Kretzschmar ME, Bootsma MCJ, Rozhnova G. Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study. *PLOS Medicine*. 2020;17(7):1–21. doi:10.1371/journal.pmed.1003166.

[36] Gatto M, Bertuzzo E, Mari L, Miccoli S, Carraro L, Casagrandi R, et al. Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proceedings of the National Academy of Sciences*. 2020;117(19):10484–10491. doi:10.1073/pnas.2004978117.

[37] Pei S, Kandula S, Shaman J. Differential effects of intervention timing on COVID-19 spread in the United States. *Science Advances*. 2020;6(49). doi:10.1126/sciadv.abd6370.

[38] Dehning J, Zierenberg J, Spitzner FP, Wibral M, Neto JP, Wilczek M, et al. Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions. *Science*. 2020;369(6500). doi:10.1126/science.abb9789.

[39] Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. *Nature Med*. 2020;26:855–860. doi:10.1038/s41591-020-0883-7.

[40] Brett TS, Rohani P. Transmission dynamics reveal the impracticality of COVID-19 herd immunity strategies. *Proceedings of the National Academy of Sciences*. 2020;117(41):25897–25903. doi:10.1073/pnas.2008087117.

[41] Davies NG, Klepac P, Liu Y, Prem K, Jit M, Pearson CAB, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nature Medicine*. 2020;26(8):1205–1211. doi:10.1038/s41591-020-0962-9.

[42] Bertuzzo E, Mari L, Pasetto D, Miccoli S, Casagrandi R, Gatto M, et al. The geography of COVID-19 spread in Italy and implications for the relaxation of confinement measures. *Nature Communications*. 2020;11(1):4264. doi:10.1038/s41467-020-18050-2.

[43] Rozhnova G, van Dorp CH, Bruijning-Verhagen P, Bootsma MCJ, van de Wijgert JHHM, Bonten MJM, et al. Model-based evaluation of school- and non-school-related measures to control the COVID-19 pandemic. *Nature Communications*. 2021;12(1):1614. doi:10.1038/s41467-021-21899-6.

[44] Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science*. 2021;371(6532):916–921. doi:10.1126/science.abe6959.

[45] Bartsch SM, O’Shea KJ, Ferguson MC, Bottazzi ME, Wedlock PT, Strych U, et al. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. *American Journal of Preventive Medicine*. 2020;59(4):493–503. doi:10.1016/j.amepre.2020.06.011.

[46] Makhoul M, Ayoub HH, Chemaitelly H, Seedat S, Mumtaz GR, Al-Omari S, et al. Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses. *Vaccines*. 2020;8(4). doi:10.3390/vaccines8040668.

- 643 [47] Matrajt L, Eaton J, Leung T, Brown ER. Vaccine optimization for COVID-19: Who to vaccinate first? Science
644 Advances. 2020;7(6). doi:10.1126/sciadv.abf1374.
- 645 [48] Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2
646 in the UK. medRxiv. 2020;doi:10.1101/2020.09.22.20194183.
- 647 [49] Borges V, Isidro J, Trovão N, Duarte S, Cortes-Martins H, Martiniano H, et al. The early dynamics of the
648 SARS-CoV-2 epidemic in Portugal. medRxiv. 2021;doi:10.1101/2021.02.22.21252216.
- 649 [50] Perra N. Non-pharmaceutical interventions during the COVID-19 pandemic: A review. Accepted for publication
650 in Physics Reports; 2021.
- 651 [51] Direção-Geral da Saúde. Ponto de Situação Atual em Portugal; 2021. Available from: [https://covid19.
652 min-saude.pt/](https://covid19.min-saude.pt/).
- 653 [52] Jing Q, Liu M, Zhang Z, Fang L, Yuan J, Zhang A, et al. Household secondary attack rate of COVID-19 and as-
654 sociated determinants in Guangzhou, China: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1141–
655 1150. doi:10.1016/S1473-3099(20)30471-0.
- 656 [53] Goldstein E, Lipsitch M, Cevik M. On the effect of age on the transmission of SARS-CoV-2 in households,
657 schools and the community. The Journal of Infectious Diseases. 2020;doi:10.1093/infdis/jiaa691.
- 658 [54] Kislaya I, Goncalves P, Barreto M, de Sousa R, Garcia AC, Matos R, et al. Seroprevalence of SARS-CoV-2
659 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19). Acta
660 Mdica Portuguesa. 2021;34(2):87–94. doi:10.20344/amp.15122.
- 661 [55] Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors Associated with COVID-19
662 Vaccine Hesitancy. Vaccines. 2021;9(3). doi:10.3390/vaccines9030300.
- 663 [56] Veldhoen M, Simas JP. Endemic SARS-CoV-2 will maintain post-pandemic immunity. Nature Reviews Im-
664 munology. 2021;21(3):131–132. doi:10.1038/s41577-020-00493-9.
- 665 [57] Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-
666 CoV-2 through the postpandemic period. Science. 2020;368(6493):860–868. doi:10.1126/science.abb5793.
- 667 [58] Saad-Roy CM, Wagner CE, Baker RE, Morris SE, Farrar J, Graham AL, et al. Immune life history,
668 vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science. 2020;370(6518):811–818.
669 doi:10.1126/science.abd7343.
- 670 [59] Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern the transition of COVID-19 to
671 endemicity. Science. 2021;371(6530):741–745. doi:10.1126/science.abe6522.

- [60] Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *European Journal of Immunology*. 2020;50(12):2025–2040. doi:<https://doi.org/10.1002/eji.202048970>.
- [61] Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Science Immunology*. 2020;5(52). doi:10.1126/sciimmunol.abe0367.
- [62] Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020;370(6521):1227–1230. doi:10.1126/science.abd7728.
- [63] Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan Wh, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nature Communications*. 2021;12(1):63. doi:10.1038/s41467-020-20247-4.
- [64] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529). doi:10.1126/science.abf4063.
- [65] Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell*. XXXX;doi:10.1016/j.cell.2021.02.037.
- [66] Contemporary Portugal Database (Pordata); 2020. Available from: <https://www.pordata.pt/>.
- [67] Mistry D, Litvinova M, Pastore y Piontti A, Chinazzi M, Fumanelli L, Gomes MFC, et al. Inferring high-resolution human mixing patterns for disease modeling. *Nature Communications*. 2021;12(1):323. doi:10.1038/s41467-020-20544-y.
- [68] Backer JA, Mollema L, Vos ER, Klinkenberg D, van der Klis FR, de Melker HE, et al. Impact of physical distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Netherlands, 2016/17, April 2020 and June 2020. *Eurosurveillance*. 2021;26(8). doi:<https://doi.org/10.2807/1560-7917.ES.2021.26.8.2000994>.
- [69] Rozhnova G, Kretzschmar ME, van der Klis F, van Baarle D, Korndewal M, Vossen AC, et al. Short- and long-term impact of vaccination against cytomegalovirus: a modeling study. *BMC Med*. 2020;18. doi:<https://doi.org/10.1186/s12916-020-01629-3>.
- [70] Carpenter B, Gelman A, Hoffman M, Lee D, Goodrich B, Betancourt M, et al. Stan: A probabilistic programming language. *J Stat Softw*. 2017;76(1):1–32. doi:10.18637/jss.v076.i01.
- [71] Diekmann O, Heesterbeek JAP, Roberts MG. The construction of next-generation matrices for compartmental epidemic models. *Journal of The Royal Society Interface*. 2010;7(47):873–885. doi:10.1098/rsif.2009.0386.

Acknowledgements

G.R., J.V., A.N., M.C.G. were supported by FCT project reference 131_596787873, awarded to G.R. M.V. was supported by the European Union H2020 ERA project (No 667824 EXCELLtoINNOV). The contribution of C.H.v.D. was under the auspices of the US Department of Energy (contract number 89233218CNA000001) and supported by the National Institutes of Health (grant number R01-OD011095).

Author contributions

G.R. conceived and supervised the study. G.R. and J.V. developed the transmission model. C.H.v.D. developed the observation model. J.V. conducted preliminary model analyses. G.R. conducted all final analyses, prepared figures and wrote the manuscript. A.N., M.C.G., M.v.B., M.E.K, and M.V. provided data, validated the model and analyses. All authors contributed to interpretation of the results, writing the final version of the manuscript and gave final approval for publication.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Figures and Tables are given at the end of the manuscript.

Correspondence

Correspondence and material requests should be addressed to Dr. Ganna Rozhnova, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, P.O. Box 85500 Utrecht, The Netherlands; email: g.rozhnova@umcutrecht.nl.

Supplementary Figures and Tables

Figure S1. Estimated hospitalization rates. The histograms of age-specific hospitalization rates estimated by the model. The solid and the dashed lines are, respectively, the medians and the 95% credible intervals based on 2,000 parameter samples from the posterior distribution.

Figure S2. Estimated model parameters. The histograms of model parameter estimates. The solid and the dashed lines are, respectively, the medians and the 95% credible intervals based on 2,000 parameter samples from the posterior distribution. Time $t = 0$ corresponds to 26 February 2020.

Figure S3. Age-specific vaccination rates. Vaccination rate (number of persons vaccinated per day) per age group calculated using the national vaccination plan (Table 1) and age distribution of various vaccination categories (Figure 4 a). The vertical lines indicate the starting dates of different phases of vaccination (Table 1). According to the current guidelines persons under 18 years old are not eligible for vaccination. In the model, we assumed that the age group of 0 to 20 years old is not vaccinated.

Figure S4. Number of vaccinated persons per age group during the vaccination rollout. These numbers were calculated using the national vaccination plan (Table 1) and age distribution of various vaccination categories (Figure 4 a). The vertical lines indicate the starting dates for vaccination of different phases of vaccination (Table 1). According to the current guidelines persons under 18 years old are not eligible for vaccination. In the model, we assumed that the age group of 0 to 20 years old is not vaccinated.

Figure S5. Infectious cases dynamics. New daily cases of SARS-CoV-2 for Scenario 4 presented in Figure 7 in the main text. The black line is the median trajectory estimated from the model. The gray shaded region corresponds to 95% credible intervals. The blue vertical lines indicate the mid-points of relaxation steps (1 April, 1 June, 1 October). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1).

Figure S6. Impact of timings of different relaxation steps. Total daily hospital admissions with COVID-19 and proportion of protected population for Scenario 4 (Figure 7 in the main text) with Step 3 occurring on 1 August instead of 1 October 2021. The hospitalization data are shown as red dots. The solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals. The blue vertical lines indicate the mid-points of relaxation steps (1 April, 1 June, 1 August). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1).

Table S1. ICPC-2 codes for morbidities specified in the Portuguese vaccination plan.

Morbidities	ICPC-2 code
Cardiac insufficiency	K75, K77
Coronary heart disease	K74, K76
Renal insufficiency	U99 and GFR < 60 ml/min
COPD	R95 or another chronic respiratory disease requiring ventilation
Diabetes	T89, T90
Neoplasm	A79, B72-74, D74-76, F74, H75, K72, L71, N74, R84-85, S77, T71, T73, U75-77, X75-77, Y77-78
Hepatic insufficiency	D97
Obesity	T82
High blood pressure	K86, K87

Figure S7. Impact of vaccine efficacies and contact rates of vaccinated individuals. Scenario 4 (Figure 7 in the main text) but with a pessimistic set of vaccine efficacies (Table S2). In addition to using a pessimistic set of vaccine efficacies, we allow for behavior compensation post-vaccination modelled as a return to pre-pandemic contact rates among vaccinated persons as compared to unvaccinated persons who may continue to have reduced contact rates due to control measures. The hospitalization data are shown as red dots. The solid lines are the median trajectories estimated from the model. The gray shaded regions correspond to 95% credible intervals. The blue vertical lines indicate the mid-points of relaxation steps (1 April, 1 June, 1 October 2021). The gray vertical lines indicate the starting dates for different vaccination phases (Table 1).

Table S2. Summary of the model parameters.

Description (unit)	Notation	Reference
Constant parameters		
Latent period (days)	$1/\alpha$	Estimated
Infectious period (days)	$1/\gamma$	Estimated
Over-dispersion parameter for the NegBinom distribution for hospitalizations	ϕ	Estimated
Initial fraction of infected persons	θ	Estimated
Probability of transmission per contact	ϵ	Estimated
Age-specific parameters*		
Force of infection for unvaccinated and vaccinated persons (1/day)	$\lambda_k(t), \lambda_k^V(t)$	Eqs. (3) and (4)
Contact rate for unvaccinated persons (1/day)	$c_{kl}(t)$	Estimated, see Table S4
Contact rate for vaccinated persons (1/day)	$c_{kl}^V(t)$	Assumed
Hospitalization rate (1/day)	ν_k	Estimated
Susceptibility of age group k relative to age group $n = 10$	β_k	Estimated
Population size of age group k	N_k	[66]
Vaccination parameters*		
Vaccination rate (1/day)	r_k	Calculated from Table 1 and Figure 4 a
Vaccine efficacy in reducing susceptibility	VE_S	94% (optimistic), 55% (pessimistic) [15, 18–23, 26]
Vaccine efficacy in reducing infectivity	VE_I	0% (optimistic), 0% (pessimistic) [15, 18–23, 26]
Vaccine efficacy in reducing hospitalization rate	VE_H	67% (optimistic), 0% (pessimistic) [15, 18–23, 26]

*Indices k and l denote the age groups $k, l = 1, \dots, n$, where $n = 10$ is the number of age groups.

Table S3. Prior distribution of the statistical model.

Parameter	Prior	Description
ϵ	Uniform(0, 1)	Flat prior
θ	Uniform($10^{-7}, 5 \cdot 10^{-4}$)	Vague prior allowing for 1 to 5000 infected individuals on day $t = 0$
ϕ	Lognormal(5, 2)	Vague prior ^a
α	InvGamma(32.25, 9.75)	99% of the prior density of α^{-1} is between 2 and 5 days
γ	InvGamma(80, 20)	95% of the prior density of γ^{-1} is between 5.3 and 8.2 days
ν_k	folded- $\mathcal{N}(0, 5)$	Vague prior, where k denotes [0, 5), [5, 10), [10, 20), [20, 30), [30, 40), [40, 50), [50, 60), [60, 70), [70, 80), 80+
$\beta_{[0,20)}$	LogNormal(log(0.23), 0.5)	Odds-ratio ^b 2.23 based on prior estimates [52]
$\beta_{[20,60)}$	LogNormal(log(0.64), 0.5)	Odds-ratio ^b 0.64 based on prior estimates [52]
ζ	$\mathcal{N}(1, 0.1)$	<i>A priori</i> , ζ should be close to 1
u_i	Uniform(0, 1)	Flat prior ($i = 1, \dots, 4$)
K_i	Exp(1)	With $K_i = 1$, the uptake of control measures takes approximately 6 days ($i = 0, \dots, 4$)
t_0	$\mathcal{N}(22, 7)$	First lockdown around 18 March 2020 (State of Emergency)
$t_1 - 2.94/K_1$	$\mathcal{N}(69, 7)$	Start of relaxation of lockdown around 4 May 2020 2020 ^c
t_2	$\mathcal{N}(203, 7)$	Further relaxation on 15 September 2020 (school opening)
t_3	$\mathcal{N}(254, 7)$	Second lockdown 05 November 2020 (State of Emergency)
t_4	$\mathcal{N}(304, 7)$	Relaxation of second lockdown on 25 December 2020

Notes: ^aThe scale parameters of the normal distributions are equal to the standard deviation. ^bThe age class 60+ is taken as a reference for the relative susceptibility, i.e., $\beta_{60+} \equiv 1$. ^cThe prior on the time of relaxation of the first lockdown is put on the time where the logistic function equals 5%. Notice that $\text{logit}(0.05) = -2.94$.

Table S4. Parameters describing contact structure.

Description (unit)	Notation*	Reference
Contact rates (1/day)		
Baseline (pre-pandemic)	b_{kl}	[67]
After the first lockdown	ζa_{kl}	ζ estimated, a_{kl} inferred using [68]
After the first relaxation	$u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$	Estimated
After the second relaxation due to school opening	$u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$	Estimated
After the second lockdown	$u_3 b_{kl} + (1 - u_3) \zeta a_{kl}$	Estimated
After the relaxation due to winter holidays	$u_4 b_{kl} + (1 - u_4) \zeta a_{kl}$	Estimated
After the third lockdown	ζa_{kl}	Assumed
After first relaxation during the vaccination rollout (Scenario 1)	b_{kl}	Assumed
After first relaxation during the vaccination rollout (Scenario 2)	$u_2 b_{kl} + (1 - u_2) \zeta a_{kl}$	Assumed
After first relaxation during the vaccination rollout (Scenario 3)	$u_1 b_{kl} + (1 - u_1) \zeta a_{kl}$	Assumed
After first, second, third relaxation during the vaccination rollout (Scenario 4)	Matrices for Scenario 3, 2, 1	Assumed
Mid-point time of the logistic function (days)		
Introduction of the first lockdown	t_0	Estimated
Relaxation after the first lockdown	t_1	Estimated
Second relaxation due to school opening	t_2	Estimated
Introduction of the second lockdown	t_3	Estimated
Relaxation due to winter holidays	t_4	Estimated
Introduction of the third lockdown	t_5	28 January 2021, Assumed
First relaxation during the vaccination rollout	t_6	1 April 2021, Assumed
Second relaxation during the vaccination rollout	t_7	1 June 2021, Assumed
Third relaxation during the vaccination rollout	t_8	1 October 2021 (main analyses), 1 August (sensitivity analyses), Assumed
Slope of the logistic function (1/day)		
Introduction of the first lockdown	K_0	Estimated
Relaxation after the first lockdown	K_1	Estimated
Second relaxation due to school opening	K_2	Estimated
Introduction of the second lockdown	K_3	Estimated
Relaxation due to winter holidays	K_4	Estimated
Introduction of the third lockdown	K_0	Assumed
First relaxation during the vaccination rollout	K_1	Assumed
Second relaxation during the vaccination rollout	K_1	Assumed
Third relaxation during the vaccination rollout	K_1	Assumed
Proportion of time a person behaves as before the pandemic		
Relaxation after the first lockdown	u_1	Estimated
Second relaxation due to school opening	u_2	Estimated
Introduction of the second lockdown	u_3	Estimated
Relaxation due to winter holidays	u_4	Estimated

*Indices k and l denote the age groups $k, l = 1, \dots, n$, where $n = 10$ is the number of age groups.